<DOC>
	<DOCNO>NCT00451906</DOCNO>
	<brief_summary>This single arm study assess safety efficacy Avastin combine platinum-containing chemotherapy regimens patient advanced recurrent non-squamous non-small cell lung cancer ( NSCLC ) . Avastin give first-line treatment combination platinum-based chemotherapy combination standard care NSCLC first-line chemotherapy use line license national prescribing information . Eligible patient receive Avastin ( 15mg/kg iv day 1 3 week cycle ) concomitantly chemotherapy . Avastin treatment continue completion chemotherapy cycle disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Platinum-Containing Chemotherapy Patients With Advanced Recurrent Non-Squamous Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically cytologically document inoperable , locally advanced ( stage III ) , metastatic ( stage IV ) recurrent NSCLC squamous cell ( tumor mix histology categorize predominant cell type ) ; ECOG PS status 02 ; life expectancy &gt; = 12weeks ; adequate renal , liver hematological function . mixed , nonsmall small cell tumor , mixed adenosquamous carcinoma predominant squamous component ; hemoptysis ( &gt; =1/2 teaspoon bright red blood ) previous 3 month ; evidence tumor invade major blood vessel image ; evidence CNS metastasis , even previously treat . major surgery ( include open biopsy ) , significant traumatic injury within 28 day prior enrolment , anticipation need major surgery study treatment ; prior chemotherapy stage IIIb/IV disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>